Surveillance and Tracking the Outcomes of Chronic Latent EBV Infection
ConditionEBV Infection
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorHuazhong University of Science and Technology
About this trial
Immunocompetent subjects with high load of Epstein-Barr virus DNA (EBV-DNA) in peripheral blood will be enrolled and prospectively followed up to track the natural histories of the chronic high load of EBV virus. The primary goal of this study is to explore the association of peripheral high load of EBV with the hematological malignancies, and second goal is to investigate the genetic mechanisms of immune escape and tumorigenesis of chronic EBV infection.
Eligibility criteria
Qualifiers
immunocompetent subjects who was found to have high EBV-DNA load （>1×103 copies/ml）in peripheral blood during the physical examination
Willing to be followed up by telephone or face-to-face interview
Disqualifiers
Subjects with defined immunodeficiency
Subjects who have taken or are going to take immunosuppressive drugs.
Subjects Diagnosed a validated hematopathy
Subjects diagnosis as precancerous lesion or malignant tumor and the life expectancy is less than 1 year.
Trial design
Treatments tested in this trial
- peripheral EBV-DNA load
Treatment groups
10,000 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov